Antiangiogenic peptides and proteins: from experimental tools to clinical drugs.

Details

Serval ID
serval:BIB_9AC240F0089F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Antiangiogenic peptides and proteins: from experimental tools to clinical drugs.
Journal
Biochimica et Biophysica Acta-Reviews on Cancer
Author(s)
Rüegg C., Hasmim M., Lejeune F.J., Alghisi G.C.
ISSN
0304-419X
ISSN-L
1879-2561
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
1765
Number
2
Pages
155-77
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review - Publication Status: ppublish
Abstract
The formation of a 'tumor-associated vasculature', a process referred to as tumor angiogenesis, is a stromal reaction essential for tumor progression. Inhibition of tumor angiogenesis suppresses tumor growth in many experimental models, thereby indicating that tumor-associated vasculature may be a relevant target to inhibit tumor progression. Among the antiangiogenic molecules reported to date many are peptides and proteins. They include cytokines, chemokines, antibodies to vascular growth factors and growth factor receptors, soluble receptors, fragments derived from extracellular matrix proteins and small synthetic peptides. The polypeptide tumor necrosis factor (TNF, Beromun) was the first drug registered for the regional treatment of human cancer, whose mechanisms of action involved selective disruption of the tumor vasculature. More recently, bevacizumab (Avastin), an antibody against vascular endothelial growth factor (VEGF)-A, was approved as the first systemic antiangiogenic drug that had a significant impact on the survival of patients with advanced colorectal cancer, in combination with chemotherapy. Several additional peptides and antibodies with antiangiogenic activity are currently tested in clinical trials for their therapeutic efficacy. Thus, peptides, polypeptides and antibodies are emerging as leading molecules among the plethora of compounds with antiangiogenic activity. In this article, we will review some of these molecules and discuss their mechanism of action and their potential therapeutic use as anticancer agents in humans.
Keywords
Angiogenesis Inhibitors, Animals, Humans, Neoplasms, Neovascularization, Pathologic
Pubmed
Web of science
Create date
28/01/2008 8:36
Last modification date
20/08/2019 15:01
Usage data